{
  "cik": 1774857,
  "cik_padded": "0001774857",
  "entityName": "Aardvark Therapeutics, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-119770",
      "filed": "2026-03-23",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 95000.0,
        "cash": 47051000.0,
        "eps_diluted": -2.93,
        "free_cash_flow": -54267000.0,
        "net_income": -57591000.0,
        "operating_cash_flow": -54172000.0,
        "operating_income": -62725000.0,
        "stockholders_equity": 106633000.0,
        "total_assets": 117181000.0,
        "total_liabilities": 10548000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.0989187212213855,
        "roa_avg2y": -0.5916235207100592,
        "roa_period_end": -0.491470460228194,
        "roe_avg2y": -2.215464512406232,
        "roe_period_end": -0.5400860896720527
      }
    },
    {
      "accn": "0001193125-26-119770",
      "filed": "2026-03-23",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 109000.0,
        "cash": 61641000.0,
        "eps_diluted": -5.15,
        "free_cash_flow": -18196000.0,
        "net_income": -20588000.0,
        "operating_cash_flow": -18087000.0,
        "operating_income": -22785000.0,
        "stockholders_equity": -54643000.0,
        "total_assets": 77507000.0,
        "total_liabilities": 5394000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.26562762073103074,
        "roe_avg2y": 0.460349935714685
      }
    },
    {
      "accn": "0001193125-26-119770",
      "filed": "2026-03-23",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -34802000.0
      },
      "period_end": "2023-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-119770",
    "filed": "2026-03-23",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001774857.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001774857.json"
  },
  "ticker": "AARD"
}